Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple drug stop deadly organ failure after surgery?

NCT ID NCT07404358

Prevention Sponsor: Botkin Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if a drug called dalargin can prevent serious organ problems like kidney injury, lung failure, or heart damage after major abdominal surgery. About 200 adults having high-risk surgery will get either dalargin or a placebo for 3 days. The goal is to see if dalargin reduces these life-threatening complications and helps people recover better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

200 people

The number who actually took part.

Started

May 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients aged 18 to 85 years. * Scheduled for elective high-risk abdominal surgery (e.g., gastrectome, pancreatectomy, colectomy) under general anesthesia. * American Society of Anesthesiologists (ASA) physical status class I-III. * Able to provide written informed consent. Exclusion Criteria: * ASA physical status class IV or V. * Acute myocardial infarction within the past 6 month. * Acute stroke within the past 6 month. * Chronic heart failure NYHA class IV. * Chronic kidney disease stage 3a or higher (according KDIGO) * Active infectious disease. * Any diagnosed phychiatric disorder (according ICD-10) confirmed be a psychiatrist. * Any neuromuscular disease (according to ICD-10) * Pregnancy or breastfeeding. * Inability to undergo preoperative assessment. * Previous enrollment in this trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abdominal surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Postoperative Complications spinocerebellar ataxia type 23 multiple organ dysfunction syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abdominal surgery Multiple organ failure Postoperative complications

Contacts and locations

Locations

  • S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center

    Moscow, 125284, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.